BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 25488931)

  • 1. Quantitative transporter proteomics by liquid chromatography with tandem mass spectrometry: addressing methodologic issues of plasma membrane isolation and expression-activity relationship.
    Kumar V; Prasad B; Patilea G; Gupta A; Salphati L; Evers R; Hop CE; Unadkat JD
    Drug Metab Dispos; 2015 Feb; 43(2):284-8. PubMed ID: 25488931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
    Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
    Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
    Elsby R; Martin P; Surry D; Sharma P; Fenner K
    Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential of Sutherlandia frutescens for herb-drug interaction.
    Fasinu PS; Gutmann H; Schiller H; James AD; Bouic PJ; Rosenkranz B
    Drug Metab Dispos; 2013 Feb; 41(2):488-97. PubMed ID: 23209194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Organic anion transporting polypeptide 2B1 and breast cancer resistance protein interact in the transepithelial transport of steroid sulfates in human placenta.
    Grube M; Reuther S; Meyer Zu Schwabedissen H; Köck K; Draber K; Ritter CA; Fusch C; Jedlitschky G; Kroemer HK
    Drug Metab Dispos; 2007 Jan; 35(1):30-5. PubMed ID: 17020956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of novel platelet-increasing agent eltrombopag with rosuvastatin via breast cancer resistance protein in humans.
    Takeuchi K; Sugiura T; Matsubara K; Sato R; Shimizu T; Masuo Y; Horikawa M; Nakamichi N; Ishiwata N; Kato Y
    Drug Metab Dispos; 2014 Apr; 42(4):726-34. PubMed ID: 24440960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ochratoxin A transport by the human breast cancer resistance protein (BCRP), multidrug resistance protein 2 (MRP2), and organic anion-transporting polypeptides 1A2, 1B1 and 2B1.
    Qi X; Wagenaar E; Xu W; Huang K; Schinkel AH
    Toxicol Appl Pharmacol; 2017 Aug; 329():18-25. PubMed ID: 28532671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.
    Reese MJ; Savina PM; Generaux GT; Tracey H; Humphreys JE; Kanaoka E; Webster LO; Harmon KA; Clarke JD; Polli JW
    Drug Metab Dispos; 2013 Feb; 41(2):353-61. PubMed ID: 23132334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of Interactions Between an Antisense Oligonucleotide with 2'-O-(2-Methoxyethyl) Modifications and Major Drug Transporters.
    Yu RZ; Warren MS; Watanabe T; Nichols B; Jahic M; Huang J; Burkey J; Geary RS; Henry SP; Wang Y
    Nucleic Acid Ther; 2016 Apr; 26(2):111-7. PubMed ID: 26959999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein.
    Matsushima S; Maeda K; Kondo C; Hirano M; Sasaki M; Suzuki H; Sugiyama Y
    J Pharmacol Exp Ther; 2005 Sep; 314(3):1059-67. PubMed ID: 15901800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
    Kulmatycki K; Hanna I; Meyers D; Salunke A; Movva A; Majumdar T; Natrillo A; Vapurcuyan A; Rebello S; Sunkara G; Chen J
    Int J Clin Pharmacol Ther; 2015 May; 53(5):345-55. PubMed ID: 25740267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transporter studies with the 3-O-sulfate conjugate of 17alpha-ethinylestradiol: assessment of human liver drug transporters.
    Han YH; Busler D; Hong Y; Tian Y; Chen C; Rodrigues AD
    Drug Metab Dispos; 2010 Jul; 38(7):1072-82. PubMed ID: 20360302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors.
    Oostendorp RL; van de Steeg E; van der Kruijssen CM; Beijnen JH; Kenworthy KE; Schinkel AH; Schellens JH
    Drug Metab Dispos; 2009 Apr; 37(4):917-23. PubMed ID: 19139163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of organic anion-transporting polypeptide 1B1- and 1B3-mediated hepatic uptake of statins based on transporter protein expression and activity data.
    Kunze A; Huwyler J; Camenisch G; Poller B
    Drug Metab Dispos; 2014 Sep; 42(9):1514-21. PubMed ID: 24989890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of hepatic drug transporter activity and expression by organochlorine pesticides.
    Bucher S; Le Vee M; Jouan E; Fardel O
    J Biochem Mol Toxicol; 2014 Mar; 28(3):119-28. PubMed ID: 24464585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor.
    Chino Y; Hasegawa M; Fukasawa Y; Mano Y; Bando K; Miyata A; Nakai Y; Endo H; Yamaguchi JI
    Xenobiotica; 2017 Apr; 47(4):314-323. PubMed ID: 27324291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin.
    Custodio JM; Wang H; Hao J; Lepist EI; Ray AS; Andrews J; Ling KH; Cheng A; Kearney BP; Ramanathan S
    J Clin Pharmacol; 2014 Jun; 54(6):649-56. PubMed ID: 24375014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between Membrane Protein Expression Levels and Transcellular Transport Activity for Breast Cancer Resistance Protein.
    Liu H; Huang L; Li Y; Fu T; Sun X; Zhang YY; Gao R; Chen Q; Zhang W; Sahi J; Summerfield S; Dong K
    Drug Metab Dispos; 2017 May; 45(5):449-456. PubMed ID: 28209803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters.
    Chu X; Cai X; Cui D; Tang C; Ghosal A; Chan G; Green MD; Kuo Y; Liang Y; Maciolek CM; Palamanda J; Evers R; Prueksaritanont T
    Drug Metab Dispos; 2013 Mar; 41(3):668-81. PubMed ID: 23293300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs.
    Ieiri I; Higuchi S; Sugiyama Y
    Expert Opin Drug Metab Toxicol; 2009 Jul; 5(7):703-29. PubMed ID: 19442037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.